The discovery of the role of bile acid receptors in a number of diseases, including cholangiocarcinoma, hepatocellular carcinoma, and colon cancer, has led to the development of novel receptor agonists for potential treatments and therapies (41). Here, NR1H4 is linked to cholangiocarcinoma.